NEW CHEMICAL ENTITY

We are developing a new chemical entity (NCE); a novel pentapolymer for treating autoimmune diseases such as MS. Our U.S. patent application with respect to our pentapolymer NCE was allowed in July 2015. We have conducted preliminary pre-clinical studies of this novel pentapolymer.